- Home
- HEPA
as 12-18-2024 12:45pm EST
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | EDISON |
| Market Cap: | 4.1M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 27.6K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.48 - $3.72 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Hepion Pharmaceuticals Inc. News
HEPA Breaking Stock News: Dive into HEPA Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.
GlobeNewswire
13 days ago
Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson’s Disease Study Group
GlobeNewswire
16 days ago
Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
GlobeNewswire
a month ago
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger
GlobeNewswire
3 months ago
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
GlobeNewswire
5 months ago
Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement
The Telegraph
6 months ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Motley Fool
6 months ago
4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow
Compare HEPA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HEPA Hepion Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.